Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review

Hepatic dysfunction, in the absence of liver metastases, occurs in 10–15% of renal cell carcinoma (RCC) patients, while immune hepatitis due to anti-CTLA4 and anti-PD1 administration affects about 3–9% and 0.7–1.8% of treated patients, respectively. Liver toxicity following combination therapy (anti...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Case Rep Intern Med
Asıl Yazarlar: Denaro, Nerina, Garrone, Ornella, Occelli, Marcella, Fea, Elena, Granetto, Cristina, Merlano, Marco Carlo, Numico, Gianmauro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SMC Media Srl 2021
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8276930/
https://ncbi.nlm.nih.gov/pubmed/34268267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12890/2021_002639
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller